Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

The GPCRact AI model goes beyond AlphaFold3 by predicting whether drugs functionally activate G-protein-coupled receptors ...

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity -- Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome ...

Cone snails deploy sophisticated venom cocktails to paralyse prey. Anthony King talks to the researchers harnessing these ...

Septerna has reported positive past Phase 1 results for SEP-631, an oral negative allosteric modulator of MRGPRX2, showing robust target engagement, functional pathway blockade, and tolerability ...

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...

Adhesion GPCRs are a large class of surface proteins that recognize chemical and mechanical stimuli in the body. The rapidly expanding body of knowledge on the therapeutic targeting of these receptors ...

This important study fills a gap in our knowledge of the evolution of GPCRs in holozoans, as well as the phylogeny of associated signaling pathway components such as G proteins, GRKs, and RIC8 ...

Orexin receptors (OXRs), including OX1R (HCRTR1) and OX2R (HCRTR2), are G protein-coupled receptors (GPCRs) that are activated by endogenous orexin peptides (OXA and OXB) and have potential ...